Silver and selenium compounds of benzimidazolium salts containing fluorine substituents: Synthesis, characterization, and evaluation of anticancer potentials

Basit Öğe Kaydı
dc.contributor.authorKarakas, Gulsen
dc.contributor.authorSerin, Suemeyya
dc.contributor.authorMumcu, Akin
dc.contributor.authorUlu, Oznur Dogan
dc.contributor.authorUlu, Ahmet
dc.contributor.authorKurucay, Ali
dc.contributor.authorAtes, Burhan
dc.date.accessioned2026-04-04T13:35:05Z
dc.date.available2026-04-04T13:35:05Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractThe applications of fluorine in the field of drug design are expanding at a rapid pace. The development of synthetic methodologies has enabled the creation of new fluorinated motifs. Benzimidazolium salts represent a significant source of N-heterocyclic carbenes (NHCs), a distinctive class of ligands. These salts have a wide range of applications due to their notable qualities. The present study encompasses the synthesis of four novel benzimidazolium salts (1a-d) substituted with 2,6-difluorobenzyl moiety. Subsequently, the prepared salts were utilized in the synthesis of silver complexes (2a-d) and selenium compounds (3a-d). The structures of all compounds were elucidated by 1H, 13C, 19F NMR, HRMS, FT-IR spectroscopies, and elemental analysis techniques. The incorporation of a fluorine atom into the molecular structure of a compound has been known to induce substantial alterations in the biological responses of mentioned compound. Therefore, the cytotoxic effect of these compounds was also evaluated using the MTT assay on HCT116 and L929 cell lines. Acridine orange (AO)/ethidium bromide (EB) staining were used for the detection of apoptosis. Notably, cytotoxicity assays showed that compound 3d displayed approximately 22-fold higher potency against HCT116 than cisplatin. Taken together, this enhanced efficacy signifies the promising role of silver and selenium compounds of benzimidazolium salts containing fluorine substituents in anticancer therapies.
dc.description.sponsorshipInonu University [FBG-2023-3144]
dc.description.sponsorshipThe authors are gratefully thankful to Icenter dotnonu University for providing financial support (Project number: FBG-2023-3144) .
dc.identifier.doi10.1016/j.ica.2025.122833
dc.identifier.issn0020-1693
dc.identifier.issn1873-3255
dc.identifier.scopus2-s2.0-105010225983
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.ica.2025.122833
dc.identifier.urihttps://hdl.handle.net/11616/109605
dc.identifier.volume587
dc.identifier.wosWOS:001531204500001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier Science Sa
dc.relation.ispartofInorganica Chimica Acta
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectSilver
dc.subjectSelenium
dc.subjectBenzimidazolium salt
dc.subjectNMR
dc.subjectcytotoxic effect
dc.subjectN -heterocyclic carbene
dc.titleSilver and selenium compounds of benzimidazolium salts containing fluorine substituents: Synthesis, characterization, and evaluation of anticancer potentials
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu